Loading
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Previous close
$1.73
+$0.14 · +8.81%
Regular session · ET · Market data may be delayed.
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Day range
Current $1.73
52-week range
Current $1.73
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
75
Undervalued
Sentiment
67
Bullish
Risk
76
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Day range
Current $1.73
52-week range
Current $1.73
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 81.36M USD | 70.84M USD | 69.56M USD | 209.91M USD | 33.92M USD |
| Cost of goods sold | 7.67M USD | 5.95M USD | 2.53M USD | 3.3M USD | 1.39M USD |
| Gross profit | 73.68M USD | 64.89M USD | 67.03M USD | 206.61M USD | 32.52M USD |
| Research and development | 104.01M USD | 109.63M USD | 127.13M USD | 186.46M USD | 158M USD |
| Selling, general, and administrative | −6.82M USD | 85.91M USD | 105.89M USD | 143.49M USD | 136.24M USD |
| Operating expenses | 182.06M USD | 195.54M USD | 233.02M USD | 329.95M USD | 294.24M USD |
| Interest income | 8.81M USD | 12.27M USD | 10.54M USD | 2.57M USD | 66K USD |
| Interest expense | 51.63M USD | 50.21M USD | 46.33M USD | 36.73M USD | 18.34M USD |
| Depreciation and amortization | 1.88M USD | 3.28M USD | 3.27M USD | 2.39M USD | 2.63M USD |
| Operating income | −108.38M USD | −130.65M USD | −165.99M USD | −123.34M USD | −261.72M USD |
| Net income | −142.62M USD | −157.85M USD | −240.05M USD | −157.13M USD | −230.03M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.50
102.31% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM4.45M0.01%78.74B USD0.19%$278.94+0.49%
iShares Biotechnology ETFIBB1.17M0.01%10.82B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO721.39K0.00%18B USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC542.86K0.04%1.32B USD0.60%$183+0.11%
iShares Russell 2000 Growth ETFIWO321.26K0.00%13.92B USD0.24%$356.78+0.94%
State Street SPDR S&P International Small Cap ETFGWX150K0.02%907.87M USD0.40%$45.56+0.93%
Vanguard Russell 2000 Value ETFVTWV92.83K0.01%1.4B USD0.06%$185.81-0.13%
Global X - Russell 2000 ETFRSSL89.25K0.01%1.42B USD0.08%$109.09+0.21%iShares Russell 2000 ETFIWMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWOState Street SPDR S&P International Small Cap ETFGWXVanguard Russell 2000 Value ETFVTWVGlobal X - Russell 2000 ETFRSSLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
